Norethindrone Acetate


Rising Pharmaceuticals, Inc.
Human Prescription Drug
NDC 16571-658
Norethindrone Acetate is a human prescription drug labeled by 'Rising Pharmaceuticals, Inc.'. National Drug Code (NDC) number for Norethindrone Acetate is 16571-658. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Norethindrone Acetate drug includes Norethindrone Acetate - 5 mg/1 . The currest status of Norethindrone Acetate drug is Active.

Drug Information:

Drug NDC: 16571-658
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Norethindrone Acetate
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Norethindrone Acetate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Rising Pharmaceuticals, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:NORETHINDRONE ACETATE - 5 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 05 Nov, 2018
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 26 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA206490
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Rising Pharmaceuticals, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1000405
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0316571658503
0316571658053
UPC stands for Universal Product Code.
UNII:9S44LIC7OJ
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Progesterone Congeners [CS]
Progestin [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
16571-658-0550 TABLET in 1 BOTTLE (16571-658-05)05 Nov, 2018N/ANo
16571-658-50500 TABLET in 1 BOTTLE (16571-658-50)05 Nov, 2018N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Norethindrone acetate norethindrone acetate norethindrone acetate norethindrone lactose monohydrate magnesium stearate cellulose, microcrystalline white to off-white flat, beveled-edge p658

Indications and Usage:

Indications and usage norethindrone acetate tablets are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. norethindrone acetate tablets are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.

Warnings:

Warnings 1 cardiovascular disorders patients with risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of vte, obesity, and systemic lupus erythematosus) should be managed appropriately. 2 visual abnormalities discontinue medication pending examination if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. if examination reveals papilledema or retinal vascular lesions, medication should be discontinued.

General Precautions:

1 general precautions • because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation • in cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. in cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated • patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree • data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. the choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy • the
pathologist should be advised of progestin therapy when relevant specimens are submitted

Dosage and Administration:

Dosage & administration therapy with norethindrone acetate tablets must be adapted to the specific indications and therapeutic response of the individual patient. secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology: 2.5 to 10 mg norethindrone acetate tablets may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. progestin withdrawal bleeding usually occurs within three to seven days after discontinuing norethindrone acetate tablets therapy. patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with norethindrone acetate tablets. endometriosis: initial daily dosage of 5 mg norethindrone acetate tablets for two weeks. dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day of norethindrone acetate tablets is reached. therapy ma
y be held at this level for six to nine months or until annoying breakthrough bleeding demands temporary termination.

Contraindications:

Contraindications • known or suspected pregnancy. there is no indication for norethindrone acetate tablets in pregnancy. (see precautions .) • undiagnosed vaginal bleeding • known, suspected or history of cancer of the breast • active deep vein thrombosis, pulmonary embolism or history of these conditions • active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction) • impaired liver function or liver disease • as a diagnostic test for pregnancy • hypersensitivity to any of the drug components

Adverse Reactions:

Adverse reactions see warnings and precautions the following adverse reactions have been observed in women taking progestins: • breakthrough bleeding • spotting • change in menstrual flow • amenorrhea • edema • changes in weight (decreases, increases) • changes in the cervical squamo-columnar junction and cervical secretions • cholestatic jaundice • rash (allergic) with and without pruritus • melasma or chloasma • clinical depression • acne • breast enlargement/tenderness • headache/migraine • urticaria • abnormalities of liver tests (i.e., ast, alt, bilirubin) • decreased hdl cholesterol and increased ldl/hdl ratio • mood swings • nausea • insomnia • anaphylactic/anaphylactoid reactions • thrombotic and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, cerebral thrombosis and embolism) • optic neuritis (which may lead to p
artial or complete loss of vision)

Use in Pregnancy:

5 pregnancy category x norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. some progestational drugs induce mild virilization of the external genitalia of female fetuses.

Pediatric Use:

7 pediatric use norethindrone acetate tablets are not indicated in children.

Description:

Description norethindrone acetate tablets, usp - 5 mg oral tablets. norethindrone acetate tablets, (17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate), a synthetic, orally active progestin, is the acetic acid ester of norethindrone. it is a white to yellowish-white, crystalline powder. norethindrone acetate tablets contain the following inactive ingredients: lactose monohydrate, magnesium stearate, and microcrystalline cellulose. meets usp dissolution test 2. structure

Clinical Pharmacology:

Clinical pharmacology norethindrone acetate induces secretory changes in an estrogen-primed endometrium. on a weight basis, it is twice as potent as norethindrone. pharmacokinetics absorption: norethindrone acetate is completely and rapidly deacetylated to norethindrone (net) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. the pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate tablets in 29 healthy female volunteers are summarized in table 1. table 1 pharmacokinetic parameters after a single dose of norethindrone acetate tablets in healthy women norethindrone acetate tablets (n=29) arithmetic mean ± sd norethindrone (net) auc (0-inf)(ng/ml*h) 166.90±56.28 c max
(ng/ml) 26.19±6.19 t max (h) 1.83±0.58 t 1/2 (h) 8.51±2.19 auc = area under the curve c max = maximum plasma concentration t max = time at maximum plasma concentration t 1/2 = half-life sd = standard deviation figure 1. mean plasma concentration profile after a single dose of 5 mg administered to 29 healthy female volunteers under fasting conditions effect of food: the effect of food administration on the pharmacokinetics of norethindrone acetate tablets has not been studied. distribution: norethindrone is 36% bound to sex hormone-binding globulin (shbg) and 61% bound to albumin. volume of distribution of norethindrone is about 4 l/kg. metabolism: norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. the majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. excretion: plasma clearance value for norethindrone is approximately 0.4 l/hr/kg. norethindrone is excreted in both urine and feces, primarily as metabolites. the mean terminal elimination half-life of norethindrone following a single dose administration of norethindrone acetate tablets is approximately 9 hours. figure 1 special populations geriatrics the effect of age on the pharmacokinetics of norethindrone after norethindrone acetate tablets administration has not been evaluated. race the effect of race on the disposition of norethindrone after norethindrone acetate tablets administration has not been evaluated. renal insufficiency the effect of renal disease on the disposition of norethindrone after norethindrone acetate tablets administration has not been evaluated. in premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in premenopausal women with normal renal function. hepatic insufficiency the effect of hepatic disease on the disposition of norethindrone after norethindrone acetate tablets administration has not been evaluated. however, norethindrone acetate tablets are contraindicated in markedly impaired liver function or liver disease. drug interactions no pharmacokinetic drug interaction studies investigating any drug-drug interactions with norethindrone acetate tablets have been conducted.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

4 carcinogenesis, mutagenesis, and impairment of fertility some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. there is no general agreement as to whether the nodules are benign or malignant. their significance with respect to humans has not been established.

How Supplied:

How supplied norethindrone acetate tablets, usp are available as: 5 mg: white to off-white, oval, flat beveled edged tablet. 'p658' is engraved on one side, and a breakline on the reverse. available as follows: bottle of 50 ndc 16571-658-05 bottle of 500 ndc 16571-658-50 store at 20º to 25ºc (68º to 77ºf) [see usp controlled room temperature]. manufactured by: novast laboratories ltd. nantong, china 226009 distributed by: rising pharmaceuticals, inc. saddle brook, nj 07663 i0093 iss. 11/2018 rev. a

Information for Patients:

2 information for the patient healthcare providers are advised to discuss the patient information leaflet with patients for whom they prescribe norethindrone acetate tablets.

Spl Patient Package Insert:

Patient information norethindrone acetate (nor-eth-in-drone as-i-teyt) tablets, usp read this patient information before you start taking norethindrone acetate tablets and read what you get each time you refill norethindrone acetate tablets. there may be new information. this information does not take the place of talking to your healthcare provider about your medical condition. what is the most important information i should know about norethindrone acetate tablets (a progestin hormone) tablets? • do not use norethindrone acetate tablets if you are pregnant, breast-feeding or are trying to conceive. • do not use norethindrone acetate tablets if you have had a previous blood clot, stroke, or heart attack. • do not use norethindrone acetate tablets if you are postmenopausal. what are norethindrone acetate tablets? norethindrone acetate tablets are similar to the progesterone hormones naturally produced by the body. what are norethindrone acetate tablets used for? norethin
drone acetate tablets are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period who are not pregnant), the treatment of endometriosis, and the treatment of irregular menstrual periods due to hormone imbalance. who should not take norethindrone acetate tablets? you should not take norethindrone acetate tablets if you are postmenopausal, pregnant or breastfeeding. you should not take norethindrone acetate tablets if you have the following conditions: • known or suspected pregnancy. norethindrone acetate tablets are not indicated during pregnancy as it may cause fetal harm when administered to pregnant women. there is an increased risk of minor birth defects in children whose mothers take norethindrone acetate tablets during the first 4 months of pregnancy (mild masculinization of the external genitalia of the female fetus, as well as hypospadias in the male fetus). if you take norethindrone acetate tablets and later find out you were pregnant, talk with your healthcare provider right away • history of blood clots in the legs, lungs, eyes, brain, or elsewhere, or a past history of these conditions • liver impairment or disease • known or suspected cancer of the breast. if you have or had cancer of the breast, talk with your healthcare provider about whether you should take norethindrone acetate tablets • undiagnosed vaginal bleeding • hypersensitivity to norethindrone acetate tablets. see the end of this leaflet for a list of all of the ingredients in norethindrone acetate tablets what are the risks associated with norethindrone acetate tablets? • risk to the fetus: norethindrone acetate tablets should not be used if you are pregnant. norethindrone acetate tablets are contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. there is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy. several reports suggest an association between mothers who take these drugs in the first trimester of pregnancy and congenital abnormalities in male and female babies. although it is not clear that these events were drug related, you should check with your healthcare provider about the risks to your unborn child of any medication taken during pregnancy. you should avoid using norethindrone acetate tablets during pregnancy. if you take norethindrone acetate tablets and later find you were pregnant when you took it, be sure to discuss this with your healthcare provider as soon as possible. • abnormal blood clotting: use of progestational drugs, such as norethindrone acetate tablets, has been associated with changes in the blood-clotting system. these changes allow the blood to clot more easily, possibly allowing clots to form in the bloodstream. if blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. these problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), visual loss or blindness (by cutting off blood vessels in the eye), or other problems. any of these conditions may cause death or serious long-term disability. call your healthcare provider right away if you suspect you have any of these conditions. he or she may advise you to stop using the drug. • eye abnormalities: discontinue norethindrone acetate tablets and call your healthcare provider right away if you experience sudden partial or complete loss of vision, blurred vision, or sudden onset of bulging eyes, double vision, or migraine. these are some of the warning signs of serious side effects with progestin therapy: • breast lumps • dizziness and faintness • changes in speech • severe headaches • chest pain • shortness of breath • pains in your legs • changes in vision call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you. common side effects include: • headache • breast pain • irregular vaginal bleeding or spotting • stomach/abdominal cramps/bloating • nausea and vomiting • hair loss other side effects include: • high blood pressure • liver problems • high blood sugar • fluid retention • enlargements of benign tumors of the uterus (“fibroids”) • vaginal yeast infections • mental depression these are not all the possible side effects of progestin and/or estrogen therapy. for more information, ask your healthcare provider or pharmacist. what can i do to lower my chances of getting a serious side effect with norethindrone acetate tablets? • talk with your healthcare provider regularly about whether you should continue taking norethindrone acetate tablets • have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. if members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often • if you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. ask your healthcare provider for ways to lower your chances of getting heart attacks general information about the safe and effective use of norethindrone acetate tablets medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. do not take norethindrone acetate tablets for conditions for which it was not prescribed. do not give norethindrone acetate tablets to other people, even if they have the same symptoms you have. it may harm them. keep norethindrone acetate tablets out of the reach of children. this leaflet provides a summary of the most important information about progestin and/or estrogen therapy. if you would like more information, talk with your healthcare provider or pharmacist. you can ask for information about norethindrone acetate tablets that is written for health professionals. what are the ingredients in norethindrone acetate tablets? norethindrone acetate tablets contain the following inactive ingredients: lactose monohydrate, magnesium stearate, and microcrystalline cellulose manufactured by: novast laboratories ltd. nantong, china 226009 distributed by: rising pharmaceuticals, inc. saddle brook, nj 07663 iss. 11/2018 rev. a

Package Label Principal Display Panel:

Package label.principal display panel rising ndc 16571-658-05 norethindrone acetate tablets, usp 5 mg orally active progestin pharmacist: please dispense with attached patient information leaflet. 50 tablets rx only rising ndc 16571-658-50 norethindrone acetate tablets, usp 5 mg orally active progestin pharmacist: please dispense with attached patient information leaflet. 500 tablets rx only 50's count container label 500's count container label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.